The Botulism drugs in development market research report provides comprehensive information on the therapeutics under development for Botulism, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Botulism. Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Botulism and features dormant and discontinued products.
GlobalData tracks 11 drugs in development for Botulism by 11 companies/universities/institutes. The top development phase for Botulism is preclinical with eight drugs in that stage. The Botulism pipeline has five drugs in development by companies and six by universities/ institutes. Some of the companies in the Botulism pipeline products market are: University of Illinois, Stony Brook University and Technical University of Braunschweig.
The key targets in the Botulism pipeline products market include Botulinum Neurotoxin Type A, Botulinum Toxin, and Botulinum Neurotoxin Type B.
The key mechanisms of action in the Botulism pipeline product include Botulinum Neurotoxin Type A Inhibitor with seven drugs in Preclinical. The Botulism pipeline products include four routes of administration with the top ROA being Intramuscular and five key molecule types in the Botulism pipeline products market including Monoclonal Antibody, and Small Molecule.
Botulism overview
Botulism is a rare but serious illness. The cause is a toxin made by a bacterium called Clostridium botulinum. It occurs naturally in soil. Food-borne botulism comes from eating foods contaminated with the toxin. Symptoms include double or blurred vision, drooping eyelids, slurred speech, difficulty swallowing, dry mouth, and muscle weakness. Treatment may include antitoxins, intensive medical care, or surgery of infected wounds.
For a complete picture of Botulism’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
